Voting Rights and Capital

Hikma Pharmaceuticals Plc 04 March 2008 Hikma Pharmaceuticals PLC - Voting Rights and Capital LONDON, 4 March 2008: Hikma Pharmaceuticals PLC (LSE: HIK) (DIFX: HIK) notifies the market that as at 29 February 2008 its capital consists of 188,053,607 ordinary shares with voting rights. There are no shares held in treasury. The above figure (188,053,607) may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, Hikma Pharmaceuticals PLC under the FSA's Disclosure and Transparency Rules. - ENDS - Enquiries: Hikma Pharmaceuticals PLC Henry Knowles +44 20 7399 2760 Company Secretary About Hikma Hikma Pharmaceuticals PLC is a fast growing multinational group focused on developing, manufacturing and marketing a broad range of both branded and non-branded generic and in-licensed pharmaceutical products. Hikma's operations are conducted through three businesses: 'Branded', 'Injectables' and 'Generics'. Hikma's operations are based principally in the Middle East and North Africa ('MENA') region, where it is a market leader and sells across 17 countries, the United States and Europe. In 2006, the Group achieved revenues of $317 million (2005 $262 million) and profit attributable to shareholders was $55 million (2005 $44 million). At 30 June 2007, the Group had over 2,700 employees. For news and other information, please visit www.hikma.com. This information is provided by RNS The company news service from the London Stock Exchange
UK 100

Latest directors dealings